SCYNEXIS is a biotech company in the US that develops products for treating fungal infections. Its lead product candidate, Ibrexafungerp, is an oral and intravenous drug for treating various fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, and invasive candidiasis. The company has research collaborations with several pharmaceutical companies to develop and commercialize ibrexafungerp.